All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, How to treat advanced refractory multiple myeloma (MM)?
How to treat advanced refractory MM?
Mohty begins by discussing some of the latest novel and investigational therapies for the treatment of advanced refractory disease. He highlights bispecific antibodies and CAR T-cell therapies, sharing some of their latest safety and efficacy data, as well as the potential future indication for CAR T-cell therapy in earlier lines based on the results of CARTITUDE-4.
Mohty concludes with a summary of the management strategies for the neurotoxicity and infection rates associated with these treatments, emphasizing monitoring and prophylaxis as key.
Relapsed/refractory multiple myeloma: what can we target next?
Nicola Giuliani, University of Parma, Parma, IT, and colleagues published a review article in the Expert Review of Hematology, which addressed current and novel targets for treating...
Autologous stem cell transplant in multiple myeloma: optimal regimens
Current status of SCT in MM: this article focuses on the ideal induction, stem-cell mobilization, conditioning, consolidation and maintenance regimens in ASCT.
Subscribe to get the best content related to multiple myeloma delivered to your inbox